drugset
drugset / Trial / NCT03427554

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris

NCT03427554 ↗

Phase 0 Completed 455 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

Bioequivalence study comparing Tretinoin Cream, 0.1% to RETIN-A®.

Timeline

Start
2017-08-21
Primary completion
2018-01-26
Completion
2018-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Tretinoin Small molecule 0.1 % Topical

Indications

acne